Clinical Trial Update: Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study of a KRAS G12V-specific T cell receptor-transduced T cell therapy for advanced pancreatic cancer, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma
• Pancreatic Neoplasms

Drugs mentioned

• Mutant KRAS G12V-specific TCR-transduced T cells (KRAS G12V-specific T cell receptor-transduced T cells)

Snippet

Sponsor: Changhai Hospital | Conditions: Pancreatic Cancer, Pancreatic Neoplasms | Phase 1, Phase 2 | Status: RECRUITING